These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8054465)

  • 21. Increased heparin cofactor II levels in women taking oral contraceptives.
    Toulon P; Bardin JM; Blumenfeld N
    Thromb Haemost; 1990 Nov; 64(3):365-8. PubMed ID: 2096488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives.
    Levine AB; Teppa J; McGough B; Cowchock FS
    Contraception; 1996 May; 53(5):255-7. PubMed ID: 8724613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA; Gettins PG
    Biochemistry; 1998 Mar; 37(10):3272-7. PubMed ID: 9521646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk.
    Rossi E; Chiusolo P; Za T; Marietti S; Ciminello A; Leone G; De Stefano V
    Thromb Haemost; 2007 Sep; 98(3):695-7. PubMed ID: 17849067
    [No Abstract]   [Full Text] [Related]  

  • 25. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.
    Farmer RD; Todd JC; Lewis MA; MacRae KD; Williams TJ
    Contraception; 1998 Feb; 57(2):67-70. PubMed ID: 9589831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral contraceptives and deep venous thrombosis with pulmonary embolism.
    Bouché RT; Medawar SJ; Dockery GL
    J Foot Surg; 1982; 21(4):297-301. PubMed ID: 7186920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An abnormal antithrombin III (AT III) with low heparin affinity: AT III Clichy.
    Aiach M; François D; Priollet P; Capron L; Roncato M; Alhenc-Gelas M; Fiessinger JN
    Br J Haematol; 1987 Aug; 66(4):515-22. PubMed ID: 3663508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.
    Hellgren M; Svensson PJ; Dahlbäck B
    Am J Obstet Gynecol; 1995 Jul; 173(1):210-3. PubMed ID: 7631684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of antithrombin III.
    Bick RL
    Semin Thromb Hemost; 1982 Oct; 8(4):276-87. PubMed ID: 6758119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.
    Koide T; Odani S; Takahashi K; Ono T; Sakuragawa N
    Proc Natl Acad Sci U S A; 1984 Jan; 81(2):289-93. PubMed ID: 6582486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells.
    Ersdal-Badju E; Lu A; Peng X; Picard V; Zendehrouh P; Turk B; Björk I; Olson ST; Bock SC
    Biochem J; 1995 Aug; 310 ( Pt 1)(Pt 1):323-30. PubMed ID: 7646463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors.
    Pabinger I; Schneider B
    Thromb Haemost; 1994 May; 71(5):548-52. PubMed ID: 8091378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin binding affinity of normal and genetically modified antithrombin III measured using a monoclonal antibody to the heparin binding site of antithrombin III.
    Watton J; Longstaff C; Lane DA; Barrowcliffe TW
    Biochemistry; 1993 Jul; 32(28):7286-93. PubMed ID: 8343518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombin III Alger: a new homozygous AT III variant.
    Fischer AM; Cornu P; Sternberg C; Mériane F; Dautzenberg MD; Chafa O; Beguin S; Desnos M
    Thromb Haemost; 1986 Apr; 55(2):218-21. PubMed ID: 3715788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral contraceptive agents and antithrombin III].
    Kamenov V; Nalbanski B
    Akush Ginekol (Sofiia); 1990; 29(1):60-3. PubMed ID: 1695492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombin 'DREUX' (Lys 114Glu): a variant with complete loss of heparin affinity.
    Mushunje A; Zhou A; Huntington JA; Conard J; Carrell RW
    Thromb Haemost; 2002 Sep; 88(3):436-43. PubMed ID: 12353073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of oral contraceptives on antithrombin III measurement.
    Petersen C; Kelly R; Minard B; Cawley LP
    Am J Clin Pathol; 1979 Jul; 72(1):134-5. PubMed ID: 453106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral contraceptives and antithrombin III: variations by dosage and ABO blood group.
    Burkman RT; Bell WR; Zacur HA; Kimball AW
    Am J Obstet Gynecol; 1991 Jun; 164(6 Pt 1):1453-8; discussion 1458-60. PubMed ID: 2048592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Budd-Chiari Syndrome and antithrombin III deficiency.
    McClure S; Dincsoy HP; Glueck H
    Am J Clin Pathol; 1982 Aug; 78(2):236-41. PubMed ID: 7102823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.